Diversified Consumer Services
Company Overview of University of Manchester
University of Manchester is an educational institution that provides undergraduate, graduate, and postgraduate programs. It offers courses in accounting and finance; aerospace engineering; anatomical science; cognitive neuroscience and psychology; computer science; economics; learning disability; modern languages and cultures; and psychology. University of Manchester was formerly known as Victoria University of Manchester and changed its name to University of Manchester in March, 2003. The university was founded in 1824 and is based in Manchester, United Kingdom.
Manchester, M13 9PL
Founded in 1824
Key Executives for University of Manchester
President and Vice-Chancellor
Director of Manchester Interdisciplinary Biocentre
Compensation as of Fiscal Year 2016.
University of Manchester Key Developments
OptiBiotix Health plc Forms Skin Health Joint Venture with the University of Manchester
Mar 18 16
OptiBiotix Health plc has acquired the exclusive rights to intellectual property developed by The University of Manchester in skin health, creating a majority owned joint venture which will be called SkinBiotix Ltd. Under the terms of the agreement, OptiBiotix have invested GBP 260,000 into the JV and will own 52% of SkinBiotix Ltd., with the remaining 48% owned by the University of Manchester and key researchers.
University of Manchester Presents at 5th Graphite & Graphene Conference 2015, Dec-09-2015 10:00 AM
Dec 7 15
University of Manchester Presents at 5th Graphite & Graphene Conference 2015, Dec-09-2015 10:00 AM. Venue: Waldorf Hilton, London, United Kingdom. Speakers: James Baker, Business Director, National Graphene Institute.
AstraZeneca and The University of Manchester Announce Collaboration
Sep 8 15
AstraZeneca and The University of Manchester announced a collaboration harnessing clinical bioinformatics to deliver personalized healthcare for cancer patients. The five-year agreement will see the organizations apply clinical trial bioinformatics to better identify the right cancer treatment for the right patient at the right time. As part of the collaboration, AstraZeneca will provide a total of £11.5 million to support clinical bioinformatics research led by a dedicated team of investigators within the recently established Centre for Cancer Biomarker Sciences at the Manchester Cancer Research Centre. The research will be carried out in partnership with the clinical trials unit of The Christie NHS Foundation Trust, which is at the forefront of experimental cancer medicine in the UK. Projects will include the development of a new bioinformatics system to capture and integrate clinical trial safety, efficacy, biomarker and drug distribution data in real time, presenting the information in the form of graphs that can be easily interpreted by clinicians to help tailor the treatment for patients. The collaboration will also support new training programmes in clinical research and pharmacokinetic and pharmacodynamic modeling for investigators to understand the distribution and clinical effects of medicines within the body. This collaboration builds on existing scientific collaborations between AstraZeneca and The University of Manchester, ranging from research into novel cancer medicines to progressing treatments for lung cancer, advancing inflammatory research and developing new drug delivery systems.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries